Establishment Labs Targets 25% Revenue Growth In 2027, With Reconstruction Sales Mostly In The Back Half
The CEO said hospital approval cycles push most reconstruction revenue into late 2027, and an FDA decision is expected at the end of this year or early next.
Establishment Labs, which makes Motiva silicone breast implants, expects 25% revenue growth in 2027, and CEO Peter Caldini said on Thursday's third-quarter earnings call that the bulk of breast reconstruction revenue within that figure will land in the second half of the year. The company is still waiting on FDA approval to sell its implants for reconstruction.
Reconstruction Is Inside The 25%
A Mizuho analyst asked whether reconstruction is baked into the 2027 target or sits on top of it. CFO Sandra Harris said the outlook reflects the business as a whole, including opportunities across the portfolio, and that regulatory timing is aligned with the company's expectation of later this year or the first quarter of next.
Caldini added that hospital review "does take a little bit longer than what we've seen in augmentation." The bulk of reconstruction revenue, he said, is in the back half of the year as part of that 25% growth.
Asked whether the approval is close, Caldini said, "We can't say that it's completed," but that the company is confident. He said the company has answered the FDA's current information request and that inspections have taken place at multiple clinical sites, including the sponsor site, which he called a routine part of the process. He expects a decision at the end of this year or the beginning of next.
Hospital Committees And 130 Key Accounts
After approval, each hospital still has to clear its value-analysis committee, the internal panel that vets new products. Caldini said reviews have taken three to six months in the past, and "it's not gonna be the number of committees. It's gonna be more around the timing."
He put the number of U.S. hospital accounts driving the majority of reconstruction volume at close to 130. Some of them will not take the company's products until the reconstruction indication arrives, he said, because they want the full suite.
The company is using its Motiva Flora tissue expander, a device used before reconstruction implants, to get in the door. Flora is now in more than 350 facilities, up 14% during the quarter. The sales force has grown to 55 reps, and Caldini said more will be added through year-end.
A Strong Quarter Behind The Outlook
Third-quarter revenue was $72 million, up 33.9% from $53.8 million a year earlier. U.S. revenue rose 119% to $26 million, while sales outside the U.S. rose 9.7% to $46 million. Adjusted EBITDA reached $6.4 million, against $1.2 million a year ago.
It was the company's first quarter of positive free cash flow, at $5.1 million. The company raised 2026 revenue guidance to more than $274 million, from $269 million to $271 million. The net loss was $10.7 million, or $0.35 per share, compared with $11.1 million a year earlier.
Management also expects the company's first full year of positive free cash flow in 2027.
Sources
- Establishment Labs Hldgs Q3 2026 Earnings Call Transcript — benzinga.com
- Establishment Labs Q3 2026 Earnings Preview | Seeking Alpha — seekingalpha.com
- Establishment Labs® Reports Third Quarter 2026 Financial Results — businesswire.com